

REMARKS

Claims 1-7 and 9 are pending in the case, Claim 8 having been previously cancelled. The Office Action restricts the claims into three groups, namely:

Group I having Claims 1-5 where A is N (the triazines),

Group II, having Claims 1-5 where A is -CH (the pyrimidines), and

Group III, having Claim 6.

The Office Action alleges that Claim 6 is directed to at least 4 processes, but acknowledges that if limited to one process of making the elected compounds it would be permitted to remain in the case.

Applicants acknowledge with appreciation that Claims 7 and 9 will be considered with whichever compound invention is elected as set forth on page 3 of the Office Action.


Applicants respectfully traverse that the present invention should be restricted. Applicants acknowledge with empathy that the Examiner is not permitted much time to search in each case, but add that the compounds are so structurally similar that it would not be an undue burden for the Examiner to permit both the triazines and the pyrimidines to remain in this one case.

However, to remove issues from the case and advance its prosecution, Applicants hereby elect Group I directed to the triazines. Applicants have also amended Claim 6 to limit it to a single process of making as requested by the Office Action.

Finally, as requested, Applicants have amended the first sentence of the specification to note that the present invention is the national stage of PCT/EP00/07096.

Applicants believe the foregoing is fully responsive to the Office Action.
Review, reconsideration and allowance of the claims is respectfully requested.

Respectfully submitted,

By 
Raymond J. Harmuth
Attorney for Applicants
Reg. No. 33,896

Bayer CropScience LP
100 Bayer Road
Pittsburgh, Pennsylvania 15205-9741
(412) 777-3916
FACSIMILE PHONE NUMBER:
(412) 777-3902
s/rmc/rjh/0175